Heart Matters

Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis.

Sponsored by Novartis Pharmaceuticals Corporation.

6/23 278623

Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out.

Sponsored by Novartis Pharmaceuticals Corporation.

6/23 278623

It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis.

Sponsored by Novartis Pharmaceuticals Corporation.

6/23 278623

With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.

A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.

The Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management will consist of five 2.5-hour virtual live sessions, June 2-4, 2023. The case-based sessions will provide an in-depth discussion of cardiac amyloidosis and its pathogenesis, diagnostic techniques and pitfalls, management strategies, mechanisms to facilitate early diagnosis, treatment and management, and challenging case studies presented by leading internationally recognized experts in transthyretin cardiac amyloidosis.

Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.

TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.

The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

Cardio-oncology is a novel field in cardiovascular medicine that has rapidly grown over the past few years. What kind of role does multidisciplinary care have in it? Dr. Javed Butler is joined by Dr. Ana Barac from the Inova Heart and Vascular Institute to take a look at where cardio-oncology is and where it could be headed.